Independent favorable prognostic factor for intracranial PFS* and OS

OutcomeVariableHazard ratio95% CIP
Intracranial PFSSRS and nivolumab0.540.32–0.920.038
fmulti-fraction SRS0.480.28–0.870.015
OSSRS and nivolumab0.510.28–0.810.019
multi-fraction SRS0.540.33–0.960.043
KPS >700.340.23–0.780.010
absent extracranial disease0.500.29–0.810.018

Abbreviations: OS, overall survival; PFS, progression-free survival;HR, hazard ratio; CI, confidence interval; *Variables with a significance of p < 0.05 at univariate analysis were included in the multivariate analysis. The following variables were evaluated: age, gender, Karnofsly Perforance Status (KPS) score, histology, extracranial disease status, systemic therapy, number of metastases, time to brain metasases development, conformity index, and irradiated volumes